Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03158246
Other study ID # Cttq-POWER
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received May 16, 2017
Last updated May 21, 2017
Start date June 1, 2017
Est. completion date March 2, 2020

Study information

Verified date May 2017
Source Cttq
Contact Li Mei
Phone +86 13671312468
Email limeilzh@sina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study compares the efficacy and safety of generic zoledronic acid (Yigu®) and original zoledronic acid (Aclasta®) in the treatment of postmenopausal osteoporotic women in China. Four hundred and sixty-six subjects will be randomised (1:1ratio) to either Yigu® 5mg IV or Aclasta® 5mg IV treatment arms.


Description:

A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis, and it significantly reduced the risk of vertebral fractures additionally.

In this research, the efficacy and safety of generic zoledronic acid injection in the treatment of postmenopausal osteoporosis will be evaluated, using original drug as control drug. It will provide evidence for reasonable clinical administrations.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 466
Est. completion date March 2, 2020
Est. primary completion date December 31, 2019
Accepts healthy volunteers No
Gender Female
Age group 46 Years to 80 Years
Eligibility Inclusion Criteria:

- Postmenopausal women between the ages of 46 and 80(cessation of menses for 12 months for any reason)

- Subjects with osteoporosis diagnosed according to the World Health Organization (WHO) criteria:they had a BMD T-score of -2.5 or less at the spine or femoral neck;or they had low bone mass,defined as BMD T-score less than -1.0 and more than -2.5 at the spine or femoral neck,with the history of fragility fracture(Fracture site included vertebra, hip,proximal humera, distal radius, distal ulna)

- Subjects signed informed consent voluntarily

Exclusion Criteria:

- Any non-primary osteoporosis skeletal disease

- Subjects with abnormal hepatic function and renal function(alanine transaminase(ALT) and aspartate transaminase(AST) are 2 times higher than the upper limits of normal(ULN);plasma creatinine concentration and blood urea nitrogen are more than 1.5 ULN or calculated creatinine clearance less than 60 ml/min)

- Subjects with serum calcium greater than 2.75 mmol/L (11.0 mg/dL) or less than 2.00 mmol/L (8.0 mg/dL)

- Subjects with severe heart disease, blood disease, mental diseases

- Subjects with cancer and other serious progressive disease

- Prior therapy with bisphosphonates within 12 months before trial entry, prior therapy with parathyroid hormone 1-34 or 1-84, estrogen, selective estrogen receptor modulators, strontium more than 2 weeks within 6 months, prior therapy with oral or intravenous glucocorticoid more than 3 months within 6 months

- Subject is hypersensitivity to experimental drugs, comparator drugs and their metabolites

- Subjects who participated in other drugs or medical devices clinical studies as subjects within 3 months before this study

- Subjects judged unfit for this study by investigators

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Generic Zoledronic Acid
Generic Zoledronic Acid (Yigu®) 5mg/100ml injection
Original Zoledronic Acid
Original Zoledronic Acid (Aclasta®) 5mg/100ml injection
Dietary Supplement:
calcium
600mg/d calcium for oral daily
vitamin D
925IU/d vitamin D for oral daily

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Cttq

Outcome

Type Measure Description Time frame Safety issue
Primary Change in BMD T-scores BMD T-scores (spine, hip and femoral neck) are determined versus baseline at the visits time 12 months
Secondary Change in BMD T-scores BMD T-scores (spine, hip and femoral neck) are determined versus baseline at the visits time 6 months
Secondary Change in Biochemical markers of bone turnover Biochemical markers of bone turnover are determined versus baseline at the visits time. Including ß-CTX and P1NP 14 days, 6 months and 12 months
Secondary Fractures incidence of fracture of all parts 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03931109 - Circulating miRNA in Primary Hyperparathyroidism
Not yet recruiting NCT03232476 - Effect of Mechanical Loading With PTH on Cortical Bone Phase 4
Completed NCT02884401 - Peri-implant Bone Changes in Post-menopausal Osteoporotic Women N/A
Completed NCT00073190 - Patient- and Physician-Based Osteoporosis Education Phase 1
Completed NCT00402441 - Risedronate in the Prevention of Osteoporosis in Postmenopausal Women Phase 4
Completed NCT03710889 - Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption Phase 3
Completed NCT00010712 - Effects of Black Cohosh on Menopausal Hot Flashes Phase 2
Recruiting NCT05058976 - Romosozumab Use to Build Skeletal Integrity Phase 4
Active, not recruiting NCT05405894 - Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
Recruiting NCT03337971 - Nutritional Supplement and Bone Health in Post-Menopausal Women N/A
Completed NCT03701113 - Milk Protein and Bone Health in Postmenopausal Women N/A
Completed NCT01381588 - The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal Women N/A
Completed NCT00383422 - Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis Phase 3
Completed NCT00549965 - Satisfaction and Compliance of Risedronate in PMO Phase 4
Completed NCT00035256 - Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis Phase 4
Completed NCT01386281 - Julina Post-marketing Surveillance for Climacteric Symptoms in Japan
Completed NCT05266261 - Use of Ibandronate in Diabetic Patients N/A
Recruiting NCT04964388 - Effect of GLP-1 Receptor Agonists on Trabecular Bone Score Phase 2
Active, not recruiting NCT03623633 - Comparative Antiresorptive Efficacy Discontinuation of Denosumab Phase 4
Recruiting NCT05575167 - Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)